Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Merck & Co., Inc. < Previous 1 2 ... 6 7 8 9 10 11 12 13 Next > Merck to Hold Third-Quarter 2022 Sales and Earnings Conference Call October 27 September 29, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Animal Health Completes Minority Investment in LeeO Precision Farming September 27, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck’s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) September 27, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Animal Health to Acquire Vence September 22, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK LYNPARZA® (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer September 22, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection September 20, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Infants and Children September 16, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Five-Year Data for Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer (NSCLC) September 11, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma September 10, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK LYNPARZA® (olaparib) in Combination With Bevacizumab, and as Monotherapy, Demonstrates Clinically Meaningful Long-Term Survival in Certain Patients With First-Line Advanced Ovarian Cancer in Exploratory Analyses of Two Phase 3 Trials September 09, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck to Present at the Morgan Stanley 20th Annual Global Healthcare Conference September 06, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Reports Strong Progress in ESG Focus Areas August 30, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck to Present New Data at ESMO 2022 Congress From Its Broad Oncology Portfolio and Promising Pipeline, Demonstrating Commitment to Improving Long-Term Survival in Multiple Types of Cancer August 29, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK LYNPARZA® (olaparib) Approved in Japan as Adjuvant Treatment for Patients With BRCA-Mutated, HER2-Negative High Recurrent Risk Breast Cancer August 25, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Receives Fast Track Designation from the U.S. FDA for MK-2060, an Investigational Anticoagulant Therapy August 23, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review August 16, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology August 16, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK LYNPARZA® (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer August 04, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma August 03, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer August 03, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Announces Second-Quarter 2022 Financial Results July 28, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Announces Fourth-Quarter 2022 Dividend July 26, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Provides Update on Phase 3 KEYNOTE-412 Trial in Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma July 20, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck and Orion Announce Global Collaboration for the Development and Commercialization of ODM-208, an Investigational Steroid Synthesis Inhibitor for the Treatment of Metastatic Castration-Resistant Prostate Cancer July 13, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Announces the Launch of the Merck Digital Sciences Studio to Help Healthcare Startups Quickly Bring their Innovations to Market June 29, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck to Hold Second-Quarter 2022 Sales and Earnings Conference Call July 28 June 29, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK LYNPARZA® (olaparib) Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer June 27, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent Patients (≥12 Years of Age) With Stage IIB or IIC Melanoma Following Complete Resection June 24, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK CDC’s ACIP Unanimously Votes to Provisionally Recommend Use of Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) as an Option for Pneumococcal Vaccination in Infants and Children June 22, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children June 22, 2022 From Merck & Co., Inc. Via Business Wire Tickers MRK < Previous 1 2 ... 6 7 8 9 10 11 12 13 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.